**To the Editor:** *Enterococcus* *faecalis*, which exists commensally in the gut in warm-blooded animals and humans, is an opportunistic pathogen that causes a variety of community-acquired and health care--associated infections, such as urinary tract and intraabdominal infections, bacteremia, and endocarditis ([@R1]). Only a few studies have assessed the relationships between clinical *E*. *faecalis* strains; strains endemic to the health care setting; and community strains residing in humans, animals, or animal-origin food ([@R2]).

Recently we showed that the emergence of high-level gentamicin-resistant (HLGR) *E*. *faecalis* among patients with infective endocarditis (IE) coincided with an increase in HLGR *E*. *faecalis* in the pig population in Denmark ([@R3]). The majority of isolates belonged to the same clonal group (sequence type \[ST\] 16), suggesting that pigs constitute a community reservoir of HLGR *E*. *faecalis*. We investigated human and porcine community reservoirs of other *E*. *faecalis* clonal types associated with IE in humans in Denmark.

A total of 20 consecutive gentamicin-susceptible *E*. *faecalis* isolates were obtained from IE patients in North Denmark Region during 1996--2002 ([Table A1](#TA.1){ref-type="table"}). Cases of IE were classified as definite (n = 12) or possible (n = 8) according to the modified Duke criteria ([@R4]). A case of community-acquired *E*. *faecalis* infection (n = 6) was defined in accordance with **strict criteria applied for methicillin-resistant *Staphylococcusaureus*** ([@R5]); otherwise, cases were deemed to be health care associated (n = 14) ([Table A1](#TA.1){ref-type="table"}). HLGR ST16 isolates recovered from 2 IE patients during the study period have been characterized ([@R3]) and were excluded from the present study.

Using multilocus sequence typing ([@R6]), we identified 14 STs among the 20 IE isolates ([Table A1](#TA.1){ref-type="table"}), then compared them with STs from 2 collections of *E*. *faecalis* isolates collected as part of the Danish Integrated Antimicrobial Resistance Monitoring and Research Program ([www.danmap.org](http://www.danmap.org)): 1) all 14 isolates recovered from community-dwelling humans in North Denmark Region during 2002--2006 with approval from the local ethics committee (\[KF\] 01-006/02), which were classified into 10 STs in this study ([Table A1](#TA.1){ref-type="table"}); and 2) 19 pig isolates from 2001 that were shown in a previous study to belong to 12 STs ([@R7]).

Among the 14 STs identified in IE isolates, 4 (ST19, ST21, ST72, and ST306) and 2 (ST40 and ST97) were also found among isolates from community-dwelling humans and pigs, respectively ([Table A1](#TA.1){ref-type="table"}). Isolates belonging to these 6 STs were further characterized by **pulsed-field gel electrophoresis (**PFGE) by using *Sma*I and grouped into PFGE pulsotypes as described ([@R3]). STs and PFGE pulsotypes (A--F) were largely concordant (ST97:A, ST72:B, ST19:C, ST40:D, ST21:E, and ST306:F), except for 2 isolates belonging to ST72 and ST40, for which PFGE banding patterns (U1 and U2, respectively) were unrelated to the major PFGE pulsotypes (A--F), and 1 ST306 isolate exhibiting the ST21-like PFGE banding pattern E ([Table A1](#TA.1){ref-type="table"}).

These findings confirm the genetic relatedness of IE isolates with those from community-dwelling humans (ST72:B, ST19:C, ST21:E, and ST306:F) and pigs (ST97:A and ST40:D). Seven (64%) of 11 IE isolates belonging to these 6 clonal types originated from IE patients with health care--associated risk factors ([Table A1](#TA.1){ref-type="table"}), which suggests that health care users are predisposed to colonization and infection with *E*. *faecalis* strains residing in human and porcine community reservoirs.

Previous reports have shown that epidemiologically distinct *E*. *faecalis* populations differ in terms of biofilm formation, virulence gene content, and antimicrobial drug susceptibility profiles ([@R2]*,*[@R8]). Therefore, we characterized all isolates with respect to these traits. Isolates were categorized into strong, medium, weak, and nonbiofilm formers by using the method of Mohamed et al. ([@R8]). The presence of 12 virulence-associated and pathogenicity island genes (*ebpA*, *gelE*, ef1824, *hylA*, ef1896, ef2347, ef2505, *hylB*, *ace*, *cbh*, *esp*, and ef0571) was investigated by using colony lysates and probes that have been described elsewhere ([@R9]). The antimicrobial drug susceptibility profiles (ampicillin, chloramphenicol, ciprofloxacin, erythromycin, gentamicin, kanamycin, linezolid, penicillin, streptomycin, teicoplanin, tetracycline, and vancomycin) were determined by the Sensititre system (Trek Diagnostic Systems, East Grinstead, UK) in accordance with Clinical and Laboratory Standards Institute guidelines ([@R10]). The isolates were generally homogenous within each clonal type in terms of biofilm formation, presence of virulence-associated and pathogenicity island genes, and resistance profiles ([Table A1](#TA.1){ref-type="table"}), further supporting that IE isolates are genetically related to those from community-dwelling humans and pigs, respectively. Notably, most IE isolates were susceptible to ampicillin (100%), penicillin (100%), vancomycin (100%), high-level gentamicin (100%), and high-level streptomycin (80%), which are the drugs of choice in therapeutic regiments for *E*. *faecalis* endocarditis.

In conclusion, our results suggest that the normal intestinal microflora of humans and pigs are community reservoirs of clinical *E. faecalis* and link 2 porcine-origin clonal types of gentamicin-susceptible *E*. *faecalis*, ST97:A, and ST40:D to IE in humans in Denmark. This finding strengthens existing evidence that pigs can be a source of serious infections in humans.
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###### Origins and molecular and phenotypic characteristics of *Enterococcus* *faecalis* isolates\*

  ID (other name)   Origin†      Setting   Sampling year   MLST†   PFGE‡   Biofilm formation   Virulence-associated genes              PAI genes    Resistance profile
  ----------------- ------------ --------- --------------- ------- ------- ------------------- --------------------------------------- ------------ ---------------------
  31438-1           IE patient   HA        1997            97      A       Weak                ebpA gelE hylA ef1896 ef2505 ace        cbh          None
  130529            IE patient   HA        2000            97      A       Weak                ebpA gelE hylA ef1896 ef2505 ace        cbh          None
  67190             IE patient   CA        2002            97      A       Weak                ebpA gelE hylA ef1896 ef2505 ace        cbh          None
  7330616-3 (D30)   Pig          NA        2001            97      A       Weak                ebpA gelE hylA ef1896 ef2505 ace        cbh          None
  28137             IE patient   HA        1996            72      B       None                ebpA gelE ef1824 hylA ef2505 hlyB ace   cbh          None
  7684              IE patient   HA        1997            72      B       Weak                ebpA gelE ef1824 hylA ef2505 hlyB ace   cbh          None
  33873             IE patient   HA        2002            72      B       Medium              ebpA gelE ef1824 hylA ef2505 hlyB ace   cbh          None
  1293              CD human     NA        2003            72      B       Medium              ebpA gelE ef1824 hylA ef2505 hlyB ace   cbh          None
  3527              CD human     NA        2006            72      B       Medium              ebpA gelE ef1824 hylA ef2505 hlyB ace   cbh          None
  1745              CD human     NA        2004            72      U1      Weak                ebpA gelE ef1824 hylA ef2505 hlyB ace   cbh          TET
  43674             IE patient   CA        1999            19      C       Medium              ebpA gelE ef2505 hlyB ace               None         ERY TET
  2247              CD human     NA        2004            19      C       Medium              ebpA gelE ef2505 hlyB ace               cbh esp      CIP ERY TET
  54869             IE patient   HA        1997            40      D       Weak                ebpA gelE hylA ef2505 hlyB ace          cbh          KAN STR TET
  7330082-2 (D1)    Pig          NA        2001            40      D       Medium              ebpA gelE hylA ef2505 hlyB ace          cbh esp      None
  7330321-1 (D27)   Pig          NA        2001            40      D       Medium              ebpA gelE hylA ef2505 hlyB ace          cbh esp      CHL ERY KAN STR TET
  7331063-5 (D37)   Pig          NA        2001            40      D       None                ebpA gelE hylA ef2505 hlyB ace          cbh          STR
  7330887-1 (D32)   Pig          NA        2001            40      U2      None                ebpA gelE hylA ef2505 hlyB ace          cbh          ERY STR
  26669             IE patient   HA        1998            21      E       Weak                ebpA gelE hylA ef2505 hlyB ace          cbh          None
  3162              CD human     NA        2005            21      E       Weak                ebpA gelE hylA ef2505 ace               cbh esp      TET
  105049            IE patient   CA        1997            306     E       Medium              ebpA gelE hylA ef1896 ef2505 ace        cbh esp      None
  127801            IE patient   CA        1999            306     F       Medium              ebpA gelE hylA ef1896 ef2505 ace        cbh esp      None
  2421              CD human     NA        2004            306     F       Medium              ebpA gelE hylA ef1896 ef2505 ace        cbh esp      None
  57690             IE patient   HA        2000            22      NA      Weak                ebpA gelE ef1824 hylA ef2505 hlyB ace   cbh          None
  20505-1           IE patient   HA        2000            30      NA      Weak                ebpA gelE hylA ef1896 ef2505 ace        esp          TET
  100087            IE patient   HA        1999            41      NA      Weak                ebpA gelE hylA ef1896 ef2505 ace        cbh esp      ERY KAN STR TET
  105158            IE patient   HA        1997            55      NA      Medium              ebpA hylA ef1896 ef2505 hlyB ace        cbh esp      CHL ERY KAN STR TET
  134125            IE patient   HA        2000            55      NA      Strong              ebpA hylA ef1896 ef2505 hlyB ace        cbh esp      CHL ERY KAN STR TET
  29783             IE patient   HA        1999            81      NA      Medium              ebpA gelE ef1824 hylA ef2505 hlyB ace   cbh ef0571   None
  120903            IE patient   CA        1999            192     NA      Medium              ebpA gelE ef1824 hylA ef2505 hlyB ace   None         TET
  107137            IE patient   HA        2001            241     NA      Weak                ebpA gelE ef1824 hylA ef2505 hlyB ace   cbh ef0571   None
  83232             IE patient   CA        1997            326     NA      Strong              ebpA gelE hylA ef1896 ef2505 ace        cbh esp      None
  1149              CD human     NA        2003            133     NA      Strong              ebpA hylA ef1896 ef2505 ace             cbh          TET
  3392              CD human     NA        2005            133     NA      Medium              ebpA hylA ef1896 ef2505 ace             cbh          None
  1732              CD human     NA        2003            141     NA      None                ebpA gelE ef1824 hylA ef2505 hlyB ace   None         CIP
  1028              CD human     NA        2003            168     NA      Strong              ebpA gelE ef1824 hylA ef2505 hlyB ace   cbh          None
  1309              CD human     NA        2003            168     NA      Strong              ebpA gelE ef1824 hylA ef2505 hlyB ace   cbh          None
  1413              CD human     NA        2003            199     NA      Medium              ebpA gelE ef1824 hylA ef2505 ace        cbh          None
  2174              CD human     NA        2004            206     NA      Weak                ebpA hylA ef2505 ace                    cbh          TET
  2041              CD human     NA        2004            327     NA      Weak                ebpA hylA ef2505 ace                    cbh          TET

\*MLST, multi-locus sequence typing; PFGE, pulsed-field gel electrophoresis; PAI, pathogenicity island; IE, infective endocarditis; CD, community-dwelling; HA, healthcare-associated infection; CA, community-acquired infection; NA, not applicable; CHL, chloramphenicol; CIP, ciprofloxacin; ERY, erythromycin, KAN, kanamycin; STR, streptomycin; TET, tetracycline. †STs from 5 pig isolates (in italics) have been published previously ([@R7]); the remaining 14 pig isolates belonging to other STs (ST1, ST6, ST16, ST26, ST47, ST63, ST96, ST98, ST99, and ST100) were not included in further analysis. ‡Isolates with similar PFGE banding patterns (\>82% relatedness) received the same letter designation (A--F) to reflect their genetic relatedness; highly divergent PFGE banding patterns were designated as unique (U) types (U1 and U2).
